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Abstract
Background: Pneumocystis jiroveci pneumonia (PCP) prophylaxis is recommended for patients with CD4 counts of
less than 200 cells/mm
3. This study examines the proportion of patients in the TREAT Asia HIV Observational
Database (TAHOD) receiving PCP prophylaxis, and its effect on PCP and mortality.
Methods: TAHOD patients with prospective follow up had data extracted for prophylaxis using co-trimoxazole,
dapsone or pentamidine. The proportion of patients on prophylaxis was calculated for each calendar year since
2003 among patients with CD4 counts of less than 200 cells/mm
3. The effect of prophylaxis on PCP and survival
were assessed using random-effect Poisson regression models.
Results: There were a total of 4050 patients on prospective follow up, and 90% of them were receiving combination
antiretroviral therapy. Of those with CD4 counts of less than 200 cells/mm
3, 58% to 72% in any given year received PCP
prophylaxis, predominantly co-trimoxazole. During follow up, 62 patients developed PCP (0.5 per 100 person-years) and
169 died from all causes (1.36/100 person-years). After stratifying by site and adjusting for age, CD4 count, CDC stage
and antiretroviral treatment, those without prophylaxis had no higher risk of PCP, but had a significantly higher risk of
death (incident rate ratio 10.8, p < 0.001). PCP prophylaxis had greatest absolute benefit in patients with CD4 counts of
less than 50 cells/mm
3, lowering mortality rates from 33.5 to 6.3 per 100 person-years.
Conclusions: Approximately two-thirds of TAHOD patients with CD4 counts of less than 200 cells/mm
3 received
PCP prophylaxis. Patients without prophylaxis had significantly higher mortality, even in the era of combination
ART. Although PCP may be under-diagnosed, these data suggest that prophylaxis is associated with important
survival benefits.
Background
Pneumocystis jiroveci pneumonia (PCP) remains a
major cause of morbidity and mortality among HIV-
infected persons presenting with advanced infection [1].
Although PCP rates have dropped in the combination
antiretroviral therapy (cART) era from 29.9 (1994-1997)
to 3.9 (2003-2007) per 1000 person-years in a US cohort
[2], PCP mortality still carries a relative mortality hazard
of 2.8, even after adjusting for cART, demographics,
CD4 cell count and viral load [2].
PCP prophylaxis has been considered the standard of
care for patients with CD4 counts of less than 200 cells/
mm
3 for more than two decades, and current guidelines
still support its use for that indication [3,4]. Co-trimoxa-
zole (trimethoprim-sulfamethoxazole, TMP-SMX)
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cystis prophylaxis, and has the advantage of being off-
patent, inexpensive and widely available. However, in
spite of guidelines and the availability of a relatively
affordable first-line agent, the use of PCP prophylaxis
remains variable in clinical practice in resource-limited
settings.
Some studies suggest that after initiation of cART, pri-
mary and secondary PCP prophylaxis can be discontin-
ued for patients with CD4 counts of less than 200 cells/
mm
3 who have achieved virological suppression [5-7].
While these data may support early discontinuation of
prophylaxis for a subset of patients with CD4 counts of
less than 200 cells/mm
3 in developed countries, it is not
clear if early discontinuation can be safely practiced in
developing countries. There is also relatively little data
describing what proportion of patients fall into this sub-
set and the clinical outcomes for not receiving PCP pro-
phylaxis, especially in different geographic settings in
the developing world.
Co-trimoxazole has efficacy against a wide range of
protozoal and bacterial infections, including toxoplas-
mosis, isosporosis, malaria, salmonellosis, nocardiosis,
and pneumococcal disease. Therefore, in addition to its
protective effect against PCP, mortality differences
might be observed due to the activity of co-trimoxazole
against these other important pathogens among immu-
nocompromised patients, even if some of these are non-
AIDS-defining illnesses. This beneficial impact is poten-
tially greater in resource-limited settings where pneumo-
coccal vaccination rates for HIV-infected persons are
low, countries with a heavy disease burden of malaria,
or countries with higher rates of diarrhoeal illness.
Walker and colleagues showed that co-trimoxazole pro-
phylaxis significantly reduced mortality and malaria
among HIV-infected adults who were on cART in Africa
[8].
This study examines the proportion of HIV-infected
patients who were receiving antiretroviral treatment and
care in the TREAT Asia HIV Observational Database
(TAHOD) with CD4 cell counts of less than 200 cells/
mm
3 who did not receive PCP prophylaxis, and its effect
on PCP and mortality. The purpose of this study was to
describe PCP prophylaxis practice in the Asia-Pacific
region, and to understand the potential impact of any
gaps between guidelines and practice on clinically
important outcomes.
Methods
Established in 2003, TAHOD is a collaborative observa-
tional cohort study involving 19 sites in the Asia-Pacific
region (see Acknowledgements). Detailed methods have
been published previously [9]. Briefly, each site recruited
approximately 200 to 300 HIV-infected patients,
including patients on cART and those not initiating
antiretroviral treatment. Recruitment was based on a
consecutive series of patients regularly attending a given
site from a particular start-up time. Ethical approval for
the study was obtained at participating sites, the data
management centre (The Kirby Institute, University of
New South Wales, Sydney, Australia), and the coordi-
nating centre (TREAT Asia/amfAR - The Foundation
for AIDS Research, Bangkok, Thailand).
The data collected in TAHOD include patient demo-
graphics, CD4 and CD8 count, HIV viral load level,
prior and new AIDS-defining illness, date and cause of
death, prior and current prescribed antiretroviral treat-
ment (ART) and prophylaxis used (with dates of both
start and stop). Data on treatment for opportunistic
infection were not collected. Data on severe adverse
events and routine laboratory testing were also collected,
depending on the availability, from each participating
sites. AIDS-defining illness, including PCP, was defined
according to 1993 Centers for Disease Control and Pre-
vention (CDC) revision of the AIDS case definition [10].
Specifically, a definitive PCP diagnosis is by micro-
scopy (histology), while a presumptive diagnosis is based
on: (i) a history of dyspnea on exertion or non-produc-
tive cough of recent onset (within the past three
months); AND (ii) chest x-ray evidence of diffuse bilat-
eral interstitial infiltrates or evidence by gallium scan of
diffuse bilateral pulmonary disease; AND (iii) response
to empirical anti-PCP therapy. Data are submitted
according to a common protocol. Upon recruitment, all
available data prior to entry to TAHOD (considered as
retrospective data) are extracted from patient case notes.
Prospective data are updated six monthly at each clinic
and transferred to the data management centre for
aggregation and analyses.
TAHOD patients were included in this analysis if they
had prospective clinical visits after enrolment. Prophy-
laxis data using co-trimoxazole, dapsone or aerosolized
pentamidine (AP) were extracted. Prophylaxis data were
checked again in each TAHOD site during the study
period to make sure the data were most reliable. Dosage
on prophylaxis is not collected in TAHOD. Prescrip-
tions of prophylaxis, as well as antiretroviral treatment,
are according to the local clinical guidelines. TAHOD
sites are encouraged to contact patients who were not
seen in the clinics in the previous 12 months.
The baseline date for this analysis was defined as the
date the patient was enrolled in TAHOD, and all
patients with at least one prospective follow-up period
were included. At enrolment, 171 patients had been
diagnosed with PCP, and these patients were subse-
quently excluded in analysis for PCP diagnosis. For ana-
lysis on all-cause mortality, all patients were included
(including the 171 patients with PCP at enrolment).
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Page 2 of 9The proportion of patients on PCP prophylaxis was
calculated for each calendar year from 2003, among
active patients who were seen in the database, and
among patients who had CD4 counts of less than 200
cells/mm
3 in each calendar year and by TAHOD sites.
Incidence rates of PCP diagnosis and all-cause mortality
were calculated after stratification by current use of PCP
prophylaxis and current CD4 cell count.
Random-effect Poisson regression with a forward step-
wise approach was used to model incidence rate ratios
(IRRs) for time to PCP diagnosis and time to all-cause
mortality. CD4 cell count, current CDC disease stage,
use of PCP prophylaxis and cART were included as
time-updated variables. Patients remained untreated
until initiating ART. Other variables considered to be
included in the analysis were age and sex. The final
multivariate model included all covariates that remained
significant at the 0.10 level (two sided). All models were
stratified for TAHOD sites. Ninety-five percent confi-
dence intervals (CIs) were calculated using the exact
Poisson distribution if there were less than 20 events
and a normal approximation if there were 20 events or
more. Sensitivity analyses were done excluding sites
with extremely low proportion of prophylaxis in patients
with CD4 counts of less than 200 cells/mm
3,w h i c h
yielded similar predictions (data not shown).
Data management and statistical analyses were per-
formed using SAS for Windows (SAS Institute Inc.,
Cary, NC, USA) and Stata (StataCorp, STATA 10.1 for
Windows, College Station, Texas 77845 USA).
Results
The analysis included a total of 4050 patients who were
enrolled in TAHOD and prospectively followed. The
median age at enrolment was 36 years (interquartile
range, IQR, 31 to 43), with 64% of patients younger
than 40 years. The majority were males (71%). At enrol-
ment, 47% of patients were at CDC stage A, 10% at
stage B, and 43% at stage C. There were 171 patients
(4% of 4050) who were diagnosed with PCP at enrol-
ment. The median CD4 count at enrolment (the latest
within six months) was 301 cells/mm
3 (IQR 168 to 442).
The annual rate of loss to follow up (defined as not
seen in clinic in the previous 12 months) was 6.8 per
100 person-years.
Overall, the median CD4 counts (IQR) was 163 (89-
261) cells/mm
3 when patients started prophylaxis and
the median time (IQR) on prophylaxis was 300 (105-
560) days. Of all patients in TAHOD, 90% were on
combination antiretroviral treatment, while 39% ever
received prophylaxis. Among patients who ever received
prophylaxis, 94% received antiretroviral treatment, and
21% of the person-years observed were on prophylaxis
after initiation of cART. The prescription of prophylaxis
varies across the TAHOD sites: median CD4 counts at
start of prophylaxis ranged from 87 to 297 cells/mm
3
and median time on prophylaxis ranged from 15 to 472
days.
Figure 1 shows the proportions of patients with CD4
counts of less than 200 cells/mm
3 and proportions of
patients (with CD4 counts of less than 200 cells/mm
3)
who were on PCP prophylaxis by calendar year. In 2003,
when TAHOD was established, close to 60% of patients
were tested with CD4 counts of less than 200 cells/
mm
3. The proportion decreases steadily between 2003
and 2009, and by 2009, approximately 20% of active
patients seen in that year were tested with CD4 counts
of less than 200 cells/mm
3. Among these patients, the
proportion of patients on PCP prophylaxis remains
stable, approximately 60%, ranging from 58% in 2007 to
72% in 2009. Across TAHOD sites, prescription of pro-
phylaxis varies, ranging from less than 30% to close to
100% in patients who had CD4 counts of less than 200
cells/mm
3, but results were consistent within sites. Co-
trimoxazole was the predominant agent used for PCP
prophylaxis (92% of all episodes), compared with dap-
sone (7%) and AP (2%).
A total of 62 PCP cases were diagnosed prospectively, a
rate of 0.50 per 100 person-years (95% CI 0.39-0.64).
Among these PCP cases, 44 were diagnosed as definitive
PCP, 14 were presumptive, and four cases were unknown
diagnosis type. Current CD4 count was the only predic-
tor of the risk of PCP diagnosis. Table 1 shows the
adjusted incident rate ratio (IRR) of PCP prophylaxis in
all patients and in patients with CD4 counts of less than
200 cells/mm
3. In both models, the risks of PCP diagno-
sis were similar whether or not a patient was receiving
PCP prophylaxis (adjusted IRR 0.95, p = 0.901 among all
patients; adjusted IRR 1.39, p = 0.560 among patients
w i t hC D 4c o u n t so fl e s st h a n2 0 0c e l l s / m m
3). As shown
in the upper half of Figure 2, the risk of PCP diagnosis,
although similar between receiving or not receiving PCP
prophylaxis in each CD4 count category, was higher in
patients with lower current CD4 counts, particularly
those with CD4 counts of less than 50 cells/mm
3.
There were 169 patient deaths during prospective fol-
low up, a rate of 1.36 per 100 person-years (95% CI
1.17-1.58). Table 2 shows the predictors of mortality.
Mortality was higher in older patients, patients with
lower CD4 counts, patients with more advanced disease
stage, and patients not receiving triple or more combi-
nation therapy (highly active ART). PCP prophylaxis
remained statistically significant in the model after
adjustment for these predictors. The risk of mortality in
patients not receiving PCP prophylaxis is more than 10
times higher than those receiving prophylaxis (adjusted
IRR 10.8, p < 0.001). The lower half of Figure 2 plots
mortality by CD4 count and PCP prophylaxis, with
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Page 3 of 9mortality decreasing as CD4 count increases. However,
the data demonstrate a marked benefit for PCP prophy-
laxis among patients with CD4 counts of less than 200
cells/mm
3, with the greatest absolute benefit in patients
with CD4 less than 50 cells/mm
3.I nt h i sp r o f o u n d l y
immunosuppressed group, PCP prophylaxis was asso-
ciated with significantly lower mortality, from 33.5 per
100 person-years to 6.3 per 100 person-years.
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Figure 1 Number of patients by CD4 count, prophylaxis and calendar year.
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In this cohort of 4050 HIV-infected patients, a sub-
stantial proportion of patients (from 58% in 2003 to
20% in 2009) had advanced immunosuppression with
C D 4c o u n t so fl e s st h a n2 0 0c e l l s / m m
3,a n dP C Pp r o -
phylaxis was indicated for them. However, only two-
thirds of these patients received PCP prophylaxis
throughout the period. Patients without prophylaxis
had a significantly higher mortality, with the effect
being most pronounced in those with the lowest CD4
cell counts. However, PCP rates were not significantly
higher among those not receiving PCP prophylaxis. It
is possible the cohort size was insufficient to demon-
strate a significant difference in this clinical endpoint.
PCP could also have been under-diagnosed because a
definitive diagnosis requires confirmatory laboratory
evidence, typically on respiratory samples obtained via
bronchoalveoloar lavage. PCP can also be misdiag-
nosed as pneumonia caused by other etiologies, includ-
ing tuberculosis.
Nevertheless, these data suggest that PCP prophylaxis,
predominantly the use of co-trimoxazole, is associated
with important survival benefits. In the pre-cART era,
the risks of developing an initial episode of PCP in
patients with CD4 counts of less than 200 cells/mm
3 by
six, 12 and 36 months were 13%, 24% and 39%, respec-
tively [11]. The pooled risk ratio of PCP prophylaxis
against PCP events, PCP-related death and all deaths
was 0.32, 0.34 and 0.83, respectively, with co-trimoxa-
zole acknowledged to be the most effective agent for
PCP prophylaxis (compared with aerosolized pentami-
dine and dapsone) [12].
Among patients receiving cART, giving prophylaxis
until CD4 counts are more than 200 cells/mm
3 was esti-
mated to prevent 343 cases of primary PCP per 1000
patients, costing US$5100 per quality-adjusted life-year
gained compared with no prophylaxis [13]. A study in
Taiwan in patients on cART showed that PCP incidence
was 2.81 per 100 person-years among 521 patients who
did not initiate or discontinued PCP prophylaxis before
achieving CD4 counts over 200 cells/mm
3, significantly
higher than the PCP incidence of 0.45 per 100 person-
years among those who continued prophylaxis until
CD4 counts were more than 200 cells/mm
3 (adjusted
risk ratio 5.32) [7].
In our study, this mortality benefit was observed even
among patients with CD4 counts over 200 cells/mm
3.
Unlike the DART African cohort, TAHOD patients
reside in the Asia-Pacific region, with almost all
TAHOD sites located in urban centres, which are
Table 1 The effect of PCP prophylaxis on PCP diagnosis (adjusted by CD4 count)
Number of
patients*
PCP
diagnosis
Person times
(year)
Rate (per 100 person-
years)
adjusted
IRR**
95% CI p value
Among all patients without PCP at enrolment (n = 3879)
Receiving PCP
prophylaxis
Yes 1567 23 2498.02 0.92 1.00
No 3439 39 9942.69 0.39 0.95 (0.397, 2.255) 0.901
CD4 count (cells/
mm
3)
< = 49 442 20 336.69 5.94 1.00
50~99 513 7 366.91 1.91 0.17 (0.053, 0.551) 0.003
100~199 1352 10 1446.18 0.69 0.06 (0.020, 0.170) < 0.001
200~299 1856 9 2130.43 0.42 0.02 (0.008, 0.073) < 0.001
300+ 3042 14 8088.58 0.17 0.01 (0.003, 0.024) < 0.001
Not available 120 2 71.91 2.78 0.16 (0.020, 1.249) 0.080
Among patients without PCP at enrolemnt and with CD4 count < 200 cells/μL (n = 1592)
Receiving PCP
prophylaxis
Yes 1109 18 1309.44 1.37 1.00
No 955 19 840.34 2.26 1.39 (0.463, 4.142) 0.560
CD4 count (cells/
mm
3)
< = 49 442 20 336.69 5.94 1.00
50~99 513 7 366.91 1.91 0.18 (0.056, 0.556) 0.003
100~199 1352 10 1446.18 0.69 0.05 (0.016, 0.143) < 0.001
* Patients could contribute to more than one categories.
** Both models were stratified by TAHOD sites.
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Page 5 of 9malaria-free for the most part. The mortality benefit of
co-trimoxazole prophylaxis therefore cannot be readily
explained by its effect on malaria. It is possible that co-
trimoxazole reduces mortality by its protective efficacy
against an array of other pathogens for which HIV-
infected persons with the lowest CD4 cell counts are at
higher risk, such as cerebral toxoplasmosis, salmonello-
sis or pneumococcal disease. A higher incidence rate of
7.83
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Figure 2 Rate of PCP diagnosis and death by prophylaxis and CD4 count.
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Page 6 of 9bacterial infections (14.48 per 100 person-years) was
observed among the Taiwan patients on cART with
C D 4c o u n t so fl e s st h a n2 0 0c e l l s / m m
3 who were not
on PCP prophylaxis compared with an incidence rate of
5.56 per 100 person-years for those taking prophylaxis
[14]. The role of vaccination and its poor uptake in
resource-limited settings is often overlooked, but if
pneumococcal vaccination rates are low for most
patients who present with advanced HIV infection, this
may account for some of the protective effect of co-tri-
moxazole prophylaxis on mortality.
It is possible that PCP prophylaxis prescribing beha-
viour might be a marker of better quality of care, or
provider compliance with treatment guidelines. Another
possible explanation for the mortality difference
observed between those who received PCP prophylaxis
compared with those who did not could be that patients
who were unable to tolerate co-trimoxazole or dapsone
prophylaxis due to rash or other toxicities and were less
able to afford the more expensive third-line agent, aero-
solized pentamidine, were more likely to go without
PCP prophylaxis. Socio-economic factors might there-
fore act as potential confounders affecting the outcomes
studied.
Among other explanations for why almost one-third
of patients with appropriate indications did not receive
PCP prophylaxis was the issue of high pill burden, espe-
cially in those with the lowest CD4 cell counts. This
was cited by some clinicians when queried about low
rates of prophylaxis from their sites. It is possible there-
fore that the effect of concomitant opportunistic infec-
tions (for which high pill burdens are a marker) could
a c c o u n tf o rt h ed i f f e r e n c ei nm o r t a l i t yb e t w e e nt h o s e
with and without PCP prophylaxis.
Other studies have examined the risk of discontinuing
PCP prophylaxis in patients with CD4 counts of less
than 200 cell/mm
3 who had achieved virological sup-
pression. However, the studies are not directly compar-
able; the COHERE study, conducted in European
cohorts, had as its primary endpoint incidence of pri-
mary PCP rather than mortality, and viral load measure-
ments were generally accessible [14]. In our analysis,
HIV viral loads did not appear to independently predict
mortality, but this should be interpreted with caution
because HIV viral load measurements were missing in a
large proportion of patients and are not routinely acces-
sible because of resource limitations. However, the dif-
ferent findings between European, African and Asian
Table 2 Predictors of mortality
Number of
patients*
Death Person times
(year)
Rate (per 100 person-
years)
adjusted
IRR**
95% CI p
value
Receiving PCP
prophylaxis
Yes 1567 29 2498.98 1.16 1.00
No 3439 140 9942.75 1.41 10.83 (6.258,
18.744)
< 0.001
Age group
Age < 40 2585 80 6650.09 1.20 1.00
Age 40+ 2011 89 5791.64 1.54 1.96 (1.287, 2.997) 0.002
CD4 count (cells/mm
3)
< = 49 442 57 337.69 16.88 1.00
50~99 513 18 366.94 4.91 0.20 (0.100, 0.400) < 0.001
100~199 1352 32 1446.18 2.21 0.08 (0.043, 0.141) < 0.001
200~299 1856 26 2130.43 1.22 0.03 (0.013, 0.049) < 0.001
300+ 3042 29 8088.58 0.36 0.01 (0.003, 0.012) < 0.001
Not available 120 7 71.91 9.73 0.13 (0.044, 0.384) < 0.001
CDC stage
Stage A 1889 42 5266.13 0.80 1.00
Stage B 474 14 1459.02 0.96 1.56 (0.723, 3.355) 0.257
Stage C 1895 113 5716.58 1.98 2.36 (1.423, 3.903) 0.001
Antiretroviral treatment
No ART 843 30 1331.76 2.25 1.00
Mono/double 96 4 152.1 2.63 0.99 (0.257, 3.792) 0.984
HAART 3597 135 10957.87 1.23 0.38 (0.219, 0.647) < 0.001
* Patients could contribute to more than one categories.
** Model was stratified by TAHOD sites.
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clinical differences between regions.
Our finding that almost one-third of this cohort with
the appropriate CD4 indication did not receive PCP pro-
phylaxis was somewhat unexpected because the
TAHOD sites comprise major urban academic centres
for HIV care and often represent the leading national
HIV treatment centres in their respective countries.
Some clinicians cited anticipation that patients’ CD4 cell
counts would rise quickly with cART treatment, and
wishing to avoid causing rash or other toxicity in
patients taking multiple medications. The precise rea-
sons for not prescribing prophylaxis in individual HIV-
infected patients were hard to examine, and retrospec-
tive collection of this information would risk introdu-
cing recall bias. More specific study plans should be
developed, aiming at prescription practice, compliance
with and tolerability of prophylaxis against PCP and
other opportunistic infections.
Several limitations should be considered in interpret-
i n gt h er e s u l t si nt h i ss t u d y .T A H O Ds u b j e c t sw e r e
recruited from patients who were considered by site
investigators to be good candidates for long-term fol-
low-up. The patients in this cohort and their treatment,
therefore, may not be truly representative of all HIV-
infected patients in the Asia-Pacific region. In addition,
data on prophylaxis adherence were not collected in
TAHOD. Allowing for these limitations and extrapolat-
ing from this data, one might speculate that PCP pro-
phylaxis rates for other HIV treatment centres could be
even lower. There were a small proportion of patients
with missing or unavailable CD4 count information,
which would, to some extent, increase the uncertainty
of our final models.
Lastly, due to the observational nature of TAHOD,
there are possible unmeasured confounders associated
with prophylaxis. As a consequence, our findings could
overestimate the benefit of prophylaxis, even after
adjustments and stratification. We therefore recommend
that the interpretation of our data be made cautiously.
Conclusions
Patients without prophylaxis had significantly higher
mortality, even in the era of combination ART, suggest-
ing that prophylaxis is associated with important survi-
val benefits. Our data highlight an important gap
between guidelines and actual practice that represents a
missed opportunity for prevention. Implementing PCP
prophylaxis according to accepted guidelines could have
a substantial impact on mortality for HIV-infected
populations in Asia, as well as Africa. These findings
also suggest that we may wish to proceed with caution
when calling for discontinuation of PCP prophylaxis for
patients who have CD4 cell counts of less than 200
cells/mm
3, even with virological suppression. When
developing protocols and guidelines for prophylaxis
against opportunistic infections, it may be prudent to be
aware of potential differences between different geo-
graphic regions and access to resources.
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